83 FR 152 pgs. 38707-38708 - Prospective Grant of Exclusive Patent License: Treatment of Type I Diabetes and its Comorbidities
Type: NOTICEVolume: 83Number: 152Pages: 38707 - 38708
Pages: 38707, 38708FR document: [FR Doc. 2018-16836 Filed 8-6-18; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: National Institutes of Health
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Treatment of Type I Diabetes and its Comorbidities
AGENCY:
National Institutes of Health, HHS.
ACTION:
Notice.
SUMMARY:
[top] The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent License to Inversago Pharma, Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications
DATES:
Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development August 22, 2018 will be considered.
ADDRESSES:
Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Michael Shmilovich, Esq., Senior Licensing and Patent Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479, phone number 301-435-5019, or shmilovm@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to Inversago Pharma, Inc.:
| HHS Reference No. | Patent No. or application No. | Filing date | Title |
|---|---|---|---|
| E-282-2012-0-US-01 | 61/725,949 | November 13, 2012 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-PCT-02 | PCT/US2013/069686 | November 12, 2013 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-US-03 | 9,765,031 | November 12, 2013 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-CA-04 | 2889697 | April 27, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-EP-05 | 13802153.0 | June 01, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-IN-06 | 3733/DELNP/2015 | May 1, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-JP-07 | 2015-542015 | May 11, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-CN-08 | 201380069389.9 | July 3, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-US-09 | 15/674,365 | August 10, 2017 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-0-US-10 | 15/674,333 | August 10, 2017 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-US-01 | 61/991,333 | May 9, 2014 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-1-US-01 | 62/171,179 | June 4, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-1-PCT-02 | PCT/US2016/035291 | June 1, 2016 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-1-EP-05 | 16728547.7 | June 1, 2016 | Cannabinoid Receptor Mediating Compounds. |
| E-282-2012-1-US-08 | 15/579,123 | December 1, 2017 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-PCT-02 | PCT/US2015/029946 | May 8, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-AU-03 | 2015255765 | November 7, 2016 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-CA-04 | 2948349 | May 8, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-EP-06 | 15728668.3 | May 8, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-CN-05 | 201580028788.X | May 8, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-IN-07 | 201637038171 | November 8, 2016 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-JP-08 | 2017-511558 | May 8, 2015 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-US-09 | 15/309,728 | November 8, 2016 | Cannabinoid Receptor Mediating Compounds. |
| E-140-2014-0-HK-10 | 17105705.6 | June 9, 2017 | Cannabinoid Receptor Mediating Compounds |
The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective exclusive patent license territory will be granted worldwide and in a field of use not broader than human therapeutics for type I diabetes and its comorbidities diabetic nephropathy, chronic kidney disease, diabetic retinopathy, and peripheral and autonomic neuropathy.
The invention covered by the patents and patent applications pertaining to HHS Ref. No. E-282-2012-0 pertain to cannabinoid receptor 1 (CN 1 R) inverse agonists. CN 1 R activation plays a key role in appetitive behavior and metabolism. Of importance as a therapeutic target here is that the receptor is expressed in both peripheral tissue as well as the central nervous system. The invention is a class of pyrazole compounds that act as CN1 receptor inverse agonists and have been shown effective at reducing obesity and its associated metabolic consequences while having no experimentally discernable neuropsychotropic side effects that are considered adverse such as the earlier antagonists rimonabant. These CN 1 R receptor compounds were developed with the goals of limiting their brain penetrance without losing their metabolic efficacy due to CN1 inverse agonism, and having a primary metabolite directly targeting enzymes involved in inflammatory and fibrotic processes associated with metabolic disorders. The patent rights cover both compositions of matter and methods of use.
The inventions covered by HHS Ref. E-140-2014-0 also pertain to pyrazole CN 1 R receptor inverse agonists. In addition, some of these compounds also have a direct inhibitory effect on inducible nitric oxide synthase (iNOS), whereas another group of the compounds directly activates AMP kinase. There is evidence that the metabolic effects of endocannabinoids are mediated by CN1 receptors in peripheral tissues. These dual-target compounds may be useful for treating metabolic disease and related conditions such as obesity and diabetes and their complications, including liver or kidney fibrosis, without the dangerous the side effects.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive patent license will be royalty bearing and may be granted unless within fifteen (15) days from the date of this published notice, the NHLBI receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent license.
Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.
Dated: July 25, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-16836 Filed 8-6-18; 8:45 am]
BILLING CODE 4140-01-P